Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASH Clinical NewsTisagenlecleucel vs. SOC as 2L Therapy of Primary R/R Aggressive B-Cell NHL: Analysis of the Phase III Belinda Study

Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & Exhibition to discover the contributing factors leading to the results, as well as how insights from this study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form